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Down syndrome (DS) is caused by trisomy of human chromosome (HSA21).  Individuals with DS display 
distinct craniofacial abnormalities including an undersized, dismorphic mandible which leads to difficulty 
with eating, breathing, and swallowing. Using the Ts65Dn DS mouse model (three copies of ~50% HSA21 
homologs), we have traced the mandibular deficit to a neural crest cell (NCC) deficiency and reduction in 
first pharyngeal arch (PA1 or mandibular precursor) at embryonic day 9.5. Previous studies have shown 
that this deficit is caused when NCC fail to migrate from the neural tube to populate the PA1 and fail to 
proliferate in the PA1.  At E9.5, Dyrk1A, a triplicated DS candidate gene, is overexpressed in the PA1 and 
may cause the NCC and PA1 deficits. We hypothesize that treatment of pregnant Ts65Dn mothers with 
Epigallocatechin-3’-gallate (EGCG), a known Dyrk1A inhibitor, will correct NCC deficits and rescue the 
undersized PA1 in trisomic E9.5 embryos. To test our hypothesis, we treated pregnant Ts65Dn mothers 
with EGCG, where embryos received treatment from either E7-E8 or E0-E9.5. Our preliminary study 
found variable increases in PA1 volume and NCC number between treatment regimens, with several 
treatment groups indicating EGCG treatment has the potential to rescue the NCC deficit in the 
mandibular precursor.  We found an increase in NCC number and PA1 volume with E7-E8 EGCG 
treatment in 21-24 somite embryos from trisomic mothers and in euploid embryos from euploid 
mothers treated from E0-E9.5.  With EGCG treatment, we also observed a decrease in the average 
somite number of embryos from trisomic mothers, but an increase in those mothers’ average litter size. 
This study is important because it helps define the specific dosage and timing of ECGC and how it may 
affect specific DS phenotypes.  These findings provide preclinical testing for a potential therapy for 
craniofacial disorders linked to DS.  
 
